The University of Texas Health Science Center at San Antonio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, The University of Texas Health Science Center at San Antonio sits in the top decile of US sponsors by registered trial count (#94 of 15,742 sponsors by registered trial count).
The University of Texas Health Science Center at San Antonio: 378 sponsored US clinical trials, 77 recruiting.
The University of Texas Health Science Center at San Antonio sponsors 378 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 264 completed. 41 of these trials are in Phase 3-4 (later-stage) and 124 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes, with 13 trials.
Top-decile sponsor footprint
The University of Texas Health Science Center at San Antonio ranks in the top decile of sponsors by registered trial count (#94 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
264 of 284 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
378 total, page 6 of 8
Intravesical BCG Administration to Patients With Invasive Bladder Cancer
NCT02365207
Effect of Healing Time on New Bone Formation Following Tooth Extraction and Ridge Preservation With Demineralized Freeze-Dried Bone Allograft
NCT02154386
Impact of COX2 on Sera Biomarkers From Obese Subjects
NCT02062255
PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer
NCT02326168
Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor
NCT01942356
Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity
NCT01836094
Neuroimaging of Diet in ADHD: Phase I
NCT01862484
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01592721
Rx for Better Breast Health
NCT02279303
Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study
NCT02298998
Case Selection and Treatment Protocol for Immediate Dental Implants in the Esthetic Zone
NCT02154581
Brief Cognitive Behavioral Treatment of Deployment-Related PTSD Symptoms in Primary Care Settings
NCT02290639
Histological Comparison of Ridge Preservation Using Mineralized FDBA Alone Versus a Combined Mineralized-Demineralized Freeze Dried Bone Allograft
NCT01924390
Isolite and Dental Treatment Under Conscious Sedation
NCT01683851
Promotora-Led Physical Activity Intervention Trial for Latinas in Texas
NCT02046343
Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors
NCT01634893
Iloperidone in Mixed States of Bipolar Disorder
NCT02413918
Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy
NCT01827618
A Prospective Study: Alveolar Ridge Augmentation Using Tenting Screws, Acellular Dermal Matrix and Combination Particulate Grafts
NCT01572298
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
NCT02311101
Choices for Latinas and Clinical Trials
NCT02529280
Frailty Study of Older Adults Getting Chemotherapy and Radiation Therapy
NCT01808833
ALS and Airway Clearance (ALSAC) Therapy
NCT04947436
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
NCT01588431
Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients
NCT01705652
Sequential Multiple Assignment Treatment for Bipolar Disorder
NCT01588457
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
NCT01403610
Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems
NCT02504931
Web-based, Interactive Professional Education for Chronic Obstructive Pulmonary Disease
NCT01377675
Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
NCT01620593
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
NCT01428128
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
NCT01439854
3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01296672
The Role of Exercise in the Treatment of PTSD Symptoms
NCT02649127
Treatment Development Targeting Severe and Persistent Negative Symptoms
NCT01550666
Esthetic, Clinical and Radiographic Outcomes of Immediately Placed Implants (Type 1) and Early Placed Implants (Type 2)
NCT01623739
Redes III Patient Navigator Qol Study
NCT02275754
Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft
NCT01588444
Effect of Age on Glucose and Lipid Metabolism
NCT01737164
Acute Effect of Exenatide on Brain Glucose Metabolism
NCT01588418
Tissue Characterization in Teeth Treated With a Regeneration Protocol
NCT00881907
Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)
NCT01069523
Vasopressin Deficiency in Hemorrhagic Shock
NCT01107314
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
NCT01023737
Effects of Hemoperitoneum Driven Carbon Monoxide on Post-Traumatic Stability and Platelet Aggregation
NCT01594034
Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM
NCT00820573
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
NCT00915200
Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
NCT01223196
Increasing Physical Activity Among Mexican American Women (The Enlace Study)
NCT00869583
Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation
NCT01066624
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 79 |
| Phase 2 | 45 |
| Phase 3 | 8 |
| Phase 4 | 33 |
Therapeutic Areas
What is open in the The University of Texas Health Science Center at San Antonio pipeline
77 recruiting of 378 indexed (20% open); 264 completed (70%).
Phase mix: 41 late (III/IV) vs 124 early (I/II) (early-phase heavy).
Top condition: Type 2 Diabetes (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
The University of Texas Health Science Center at San Antonio: open-pipeline peers nationwide
Peers matched on 378 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
The University of Texas Health Science Center at San Antonio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 378 trials (± recruiting share)
- Northwell Health · 370 trials · 22% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
Sponsors near 20% open enrollment (± trial volume)
- M.D. Anderson Cancer Center · 20% recruiting · 2,692 trials
- University of Georgia · 20% recruiting · 59 trials
- University of Houston · 20% recruiting · 64 trials
- Florida International University · 20% recruiting · 89 trials
Related
What to do with this The University of Texas Health Science Center at San Antonio page
378 registered trials is a research-attention snapshot, not an endorsement of The University of Texas Health Science Center at San Antonio or any single study.
- 77 of The University of Texas Health Science Center at San Antonio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 2 Diabetes is the condition The University of Texas Health Science Center at San Antonio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. The University of Texas Health Science Center at San Antonio pipeline card: 378 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.